Stockholders’ Equity |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity |
6. Stockholders’ Equity
Common stock
During the six months ended March 31, 2021, the Company sold common stock of 10.6 million and net proceeds of $10.2 million. shares under an at-the-market sales agreement for gross proceeds of an aggregate of $
Common stock warrants
As of March 31, 2022, the following equity-classified warrants and related terms were outstanding:
During the six months ended March 31, 2021, the Series B warrant holders exercised 2. An additional of Series B warrants were net share settled, resulting in the issuance of shares of common stock. warrants for proceeds of $
During the six months ended March 31, 2021, the Chanticleer warrants to purchase 186,161 shares of common stock with an exercise price of $0.01 per share were net share settled, resulting in the issuance of shares of common stock.
|